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Objectives: Subthalamic nucleus deep brain stimulation (STN-DBS) for motor symptoms of Parkinson’s
disease (PD) is promising. However, the beneﬁts of STN-DBS are uneven for the cardinal motor symp-
toms, as well as for mentality and activities of daily living as the disease progresses. In this report, we will
try to clarify which target symptoms have long-term effects during 7 years of STN-DBS.
Materials and Methods: From February 2002 to February 2011, 120 PD patients who underwent STN-DBS
were enrolled in this cross-sectional study. Data analysis was performed at postoperative follow-up
periods of 1 year, 2 years, 5 years, and 7 years. The Uniﬁed Parkinson's Disease Rating Scale (UPDRS)
was evaluated in four combinations of levodopa/DBS, on/off.
Results: With levodopa off/DBS on, the UPDRS Part III score improved signiﬁcantly within the 7 years of
follow-up (p < 0.001). Decrements in the degree of improvement in axial symptoms were observed after
the 5th year. Despite signiﬁcant improvement in the UPDRS Part II during the 7 years of follow-up, the
score of the Schwab and England Activities of Daily Living Scale declined after the 5th year of DBS. With
levodopa off/DBS off, the scores for Part III and all subitems deteriorated in comparison with the pre-
operative levodopa off score after the 5th year of follow-up. Bradykinesia was signiﬁcantly worse in the
5th and 7th years (p < 0.05 and p < 0.01, respectively) and the axial component was signiﬁcantly worse in
the 7th year (p < 0.05). Stimulation side effects included hypophonia (20.8%), dysarthria (15%), sialorrhea
(14.2%), and decreased memory (14.2%). Other surgically related adverse effects included intracranial
hemorrhage (3.3%), pulmonary edema (N ¼ 3), deep vein thrombosis (N ¼ 1), seizure (N ¼ 1), depression
(N ¼ 7), and mania/hypomania (N ¼ 11). Five electrodes were revised and two devices became infected.
DBS stimulation parameters remained stable except for a signiﬁcant reduction in frequency in the 7th
year.
Conclusion: Long-term effects of DBS on motor disability are promising. DBS showed uneven beneﬁcial
effects, and least improvement in axial symptoms and verbal ﬂuency. The disease progressed despite
signiﬁcant positive effects of DBS on the cardinal motor disability symptoms of PD and quality of life at
7 years.
Copyright  2013, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.euroscience, Department of
, Section 3, Chung-Yang Road,
86 3 8463164.
Y. Chen).
ddhist Compassion Relief Tzu Chi1. Introduction
Subthalamic nucleus deep brain stimulation (STN-DBS) has
widely been accepted as an effective surgical modality to improve
all cardinal symptoms of Parkinson’s disease (PD) including axial
symptomatology [1,2]. In recent years, randomized trials have
suggested that STN-DBS is superior to the best medical treatment
available for advanced PD in terms of temporal domain and qualityFoundation. Published by Elsevier Taiwan LLC. All rights reserved.
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worst to STN-DBS in the short and long term should be identiﬁed to
avoid unwarranted expectations from patients, care givers, and
physicians prior to surgery [3].
DBS was developed in 1987 and was ﬁrst applied for the treat-
ment of PD in 1993 [4]. Clinical achievements have outweighed
surgical complications even though the underlying mechanisms of
action are inconclusive [5]. Nevertheless, the application of DBS has
now been extended to psychiatric diseases, epilepsy, and cognitive
impairment. DBS may modify clinical presentations and attenuate
disabilities, but seems unable to stop disease progression [6].
Although DBS is the optimal surgical alternative for treating PD,
the procedure has associated risks and stimulation-related adverse
effects. Although these side effects can be transient andminor, they
can impact a patient’s life signiﬁcantly. Those side effects may be
caused by complicated surgical procedures or hardware problems,
can be stimulation induced, or can be the dual effects of DBS and
dopaminergic medications. Therefore, most DBS centers emphasize
the need for an enthusiastic team that includes experts from
different ﬁelds of interest.
High-frequency stimulation is themajor parameter contributing
to the abolition of PD symptoms [7]. A frequency of 130 Hz is
generally used as the initial setting, and this seldom changes during
chronic stimulation. However, the optimal settings for frequency
and associated stimulating parameters in chronic stimulation are
debated.
The goals of this study are to clarify target symptoms that have
shown a sustained effect, the average stimulation parameters, and
procedure-related adverse effects during 7 years of STN-DBS.2. Materials and methods
2.1. Patients
A total of 120 consecutive PD patients who underwent STN-DBS
surgery by the operative team at Tzu Chi General Hospital, Hualien,
Taiwan, between February 2002 and February 2011 were enrolled
in this study. The diagnosis of PD followed the diagnostic criteria of
the United Kingdom PD Society Brain Bank [8]. The inclusion
criteria for STN-DBS included the following: (1) good levodopa
response on the Uniﬁed Parkinson's Disease Rating Scale (UPDRS)
Part III (motor; >30%); (2) drug-related complications (e.g., dyski-
nesia, or “oneoff phenomenon”) even under optimal anti-
parkinsonian medication adjustment; (3) no structural lesions onTable 1
Clinical and demographic data of PD patients for STN-DBS.
Preoperatively (N ¼ 120) 1 year
Mean  SD Mean
Sex (F/M) 47/73 33/
Age at onset 49.5  11.6 49.4 
Age at DBS surgery 59.3  11.1 59.1 
Disease duration at DBS surgery (years) 9.8  5.1 9.7 
Follow-up period (months) 11.2 
MMSE (N ¼ 104) 26.2  4.1
H & Y Stage 3.3  0.9
SEADL Score (%) 69.7  27.3
LEDD 779.1  389.5
L-dopa responsive rate (%) (N ¼ 119)
UPDRS Part I 22.8  28.9
Part II 42.2  27.0
Part III 41.9  18.3
Part IV 0.2  4.9
Total 37.7  17.6
PD ¼ Parkinson’s disease; STN-DBS ¼ subthalamic deep brain stimulation.
Data presented as mean  SD.brain magnetic resonance imaging (MRI); and (4) absence of
dementia.
The mean age of these patients at the time of surgery was
59.3  11.1 years. The average duration of disease prior to surgery
was 9.8  5.1 years, and the average Hoehn and Yahr staging was
3.3  0.9 in the off medication state. Prior to surgery, all patients
showed signiﬁcant levodopa responsiveness in the UPDRS Part III
(41.9  18.3%; Table 1).
All patients participating in this study signed informed consents
for STN-DBS surgery and the procedures involved in the study. The
study protocol was approved by our institutional review board (IRB
097-32; Tzu Chi General Hospital, Hualien, Taiwan).
2.2. Surgical procedures
A Leksell frame was used for the stereotactic procedure. Images
for targeting were obtained from a 1.5/3.0-Tesla MRI unit (General
Electric, Milwaukee, WI, USA). The standard settings for preoper-
ative targeting included T1-weighted axial images [repetition time
(TR): 26milliseconds; echo time (TE): 6.9 milliseconds; matrix size:
256  192; thickness: 0.7 mm] and T2-weighted axial images (TR:
4800 milliseconds; TE: 95 milliseconds; matrix size: 256  192;
thickness: 2.0 mm). Each of these sequences was performed in
contiguous axial slices. The images were transferred to a neuro-
navigation workstation (VectorVision; BrainLab, Feldkirchen, Ger-
many, or StealthStation;Medtronic, MN, USA). T1 imageswere used
for identifying and measuring the length of the anterior and pos-
terior commissures. The tentative surgical target coordinates for
the tip of the permanent implantable electrode were set at the
central border of the STN, which is near the intersection between
the line of the anterior border and 2 mm lateral to the red nucleus
on T2 images. Quadripolar DBS electrodes (model 3389, Medtronic)
were implanted after microelectrode recording (Leadpoint; Med-
tronic). After 1 week, the electrode cables were connected to an
implantable pulse generator (Soletra or Kinetra; Medtronic). The
surgical procedures have been described in detail in our previous
study [9]. An acute stimulation test was performed 1 week after
surgery to select the optimal stimulation contact and parameters
for chronic stimulation.
2.3. Clinical evaluations
Mentation, behavior and mood, activities of daily living (ADL),
severity of motor symptoms, and levodopa-related complications(N ¼ 88) 2 years (N ¼ 60) 5 years (N ¼ 31) 7 years (N ¼ 17)
 SD Mean  SD Mean  SD Mean  SD
55 22/38 7/24 4/13
12.1 47.2  12.7 44.9  12.9 43.2  10.8
11.5 57.5  11.7 54.9  12.4 52.9  11.3
4.9 10.3  5.5 10.0  5.1 9.7  2.7
2.7 25.8  4.0 57.3  7.8 82.2  6.3
Table 2
In the state of levodopa Off DBS On, UPDRS sections I, II, III and IV at different follow-up periods.
UPDRS Preoperatively (N ¼ 120) 1 year DBS (N ¼ 88) 2 years DBS (N ¼ 60) 5 years DBS (N ¼ 31) 7 years DBS (N ¼ 17)
Mean  SD Mean  SD Mean  SD Mean  SD Mean  SD
Part I 4.6  2.8 2.9  1.9*** 2.9  2.1*** 3.3  1.9* 3.8  2.0
Part II 21.0  9.3 12.8  7.8*** 12.8  7.8*** 14.3  7.4*** 14.6  7.9**
Part III 45.6  14.7 27.1  11.1*** 26.7  11.6*** 28.7  10.1*** 28.8  13.6***
Brady 19.0  6.0 13.2  5.0*** 12.8  4.9*** 14.5  4.7*** 14.3  6.6**
Tremor 5.8  5.2 1.4  2.2*** 1.6  2.8*** 1.0  1.5*** 0.9  1.3***
Rigidity 9.7  4.1 4.8  3.2*** 4.4  3.3*** 5.1  3.3*** 4.7  4.6***
Posture & gait 4.1  1.8 2.7  1.5*** 2.7  1.7*** 3.1  1.4** 3.2  1.6*
Axial 9.3  4.0 6.7  3.4*** 6.8  3.7*** 7.0  3.0** 7.5  3.6
Part IV 5.5  3.8 1.7  1.9*** 1.8  2.2*** 1.9  2.4*** 1.8  1.9***
Total 76.7  25.6 44.6  19.8*** 44.2  20.9*** 48.2  17.7*** 49.0  22.5***
H & Y stage 3.3  0.9 2.7  0.8*** 2.7  0.7*** 2.8  0.7*** 2.9  0.9
SEADL score (%) 69.7  27.3 86.7  19.2*** 87.2  17.1*** 80.3  22.4* 78.2  24.0
LEDD 779.1  389.5 425.1  258.4*** 425.3  226.6*** 567.1  359.3** 514.2  402.8**
LEDD reduction (%) 39.0  35.9 36.5  37.4 10.0  70.8 16.8  68.6
MMSE (N ¼ 104) 26.2  4.1 26.0  4.9 25.0  6.3 23.9  7.5 24.2  7.6
Med ¼ anti-parkinsonian medication; DBS ¼ deep brain stimulation; UPDRS ¼ Uniﬁed Parkinson’s Disease Rating Scale.
Data presented as mean  SD, data in parentheses of LEDD represent reduction percentage compared with pre-operation.
*p < 0.05, ** p < 0.01, ***p < 0.001.
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surgery and 1 year, 2 years, 5 years, and 7 years after surgery. The
“medication off” status in the motor examination was evaluated at
least 12 hours after withdrawal of dopaminergic medication, as
deﬁned by the Core Assessment Program for Surgical Interventional
Therapy in PD [10]. The magnitude of the levodopa response in
“medication on” state was assessed after administration of a dose of
levodopa/benserazide (Roche Products; Roche, Basel, Switzerland)
equivalent to or 1.5 times the usual morning dose. Bradykinesia
scores included items 23, 24, 25, 26, and 31 of the UPDRDS Part III.
Evaluation of the axial scores included subitems 18 (speech), 27
(rising from a chair), 28 (posture), 29 (gait), and 30 (posture
instability) of the UPDRS. All patients were evaluated post-
operatively in four conditions: (1) stimulation “off” and medication
“off”dafter DBS was switched off for at least 4 hours and the pa-
tient had no dopaminergic treatment for 12 hours; (2) stimulation
“on” andmedication “off”dafter stimulationwas switched on for at
least 2 hours; (3) stimulation “off” and medication “on”; and (4)
stimulation “on” and medication “on”.Fig. 1. Scores on the UPDRS Parts I, II, III, and IV during follow-up with levodopa off/DBS
*p < 0.05; **p < 0.01; ***p < 0.001.The total amount of antiparkinsonian medicationwas expressed
as the levodopa equivalent daily dosage (LEDD), which is the sum of
the following: the dose of regular levodopaebenserazide (or levo-
dopaecarbidopa), 0.75 times the dose of controlled-release levo-
dopaebenserazide (or levodopaecarbidopa), 10 times the dose of
bromocriptine, and 25 times the dose of ropinirole. In patients
taking entacapone, the dose was multiplied by a factor of 1.25 [11].
Cognition and memory were evaluated with the UPDRS Part I
and minimental state examination. The extent of dependency in
daily living was examined with the UPDRS Part II and Schwab and
England Activities of Daily Living Scale (SEADL).
2.4. Statistical analysis
Descriptive statistics (mean and standard deviation) were used
for continuous variables, whereas categorical variables were
described as percentages. Themain UPDRS section scores (Parts I, II,
III, and IV) and LEDD, which were considered continuous variables
and collected at different times (baseline and 1 year, 2 years, 5on. DBS ¼ deep brain stimulation; UPDRS ¼ Uniﬁed Parkinson's Disease Rating Scale.
Table 3
In the state of levodopa Off DBS Off, UPDRS sections I, II, III and IV at different follow-up periods.
UPDRS Preoperatively (N ¼ 120) 1 year DBS (N ¼ 84) 2 years DBS (N ¼ 55) 5 years DBS (N ¼ 31) 7 years DBS (N ¼ 17)
Mean  SD Mean  SD Mean  SD Mean  SD Mean  SD
Part I 4.6  2.8 4.2  2.3 3.7  2.3 4.9  2.1 5.5  1.8
Part II 21.0  9.3 21.5  10.2 21.6  9.3 26.9  9.7** 29.5  10.4***
Part III 45.6  14.7 45.6  15.2 45.2  15.1 50.4  14.2 52.9  14.8
Brady 19.0  6.0 19.2  6.2 19.4  6.1 21.5  5.7* 23.3  6.4**
Tremor 5.8  5.2 6.0  4.9 5.9  5.2 6.7  5.6 4.9  4.0
Rigidity 9.7  4.1 9.2  3.8 9.2  3.9 9.9  3.8 10.8  4.5
Posture & gait 4.1  1.8 4.0  1.9 3.8  1.8 4.5  1.6 4.8  2.1
Axial 9.3  4.0 9.3  4.3 9.0  3.7 10.3  4.0 11.9  5.0*
Part IV 5.5  3.8 4.7  3.1 4.7  3.3 4.7  2.3 4.2  2.4
Total 76.7  25.6 75.9  26.8 75.2  26.0 86.8  25.2 92.1  25.9*
H & Y stage 3.3  0.9 3.2  0.9 3.1  0.8 3.6  0.9 3.8  1.0 *
SEADL score (%) 69.7  27.3 70.9  25.4 72.2  21.8 53.2  27.7** 47.6  29.9**
MMSE (N ¼ 104) 26.2  4.1 26.2  4.8 25.8  4.8 23.7  7.6 23.9  7.5
Med ¼ anti-parkinsonian medication; DBS ¼ deep brain stimulation; UPDRS ¼ Uniﬁed Parkinson’s Disease Rating Scale.
Data presented as mean  SD, data in parentheses of LEDD represent reduction percentage compared with pre-operation.
*p < 0.05, ** p < 0.01, ***p < 0.001.
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generalized estimating equations. Post hoc comparison with the
Bonferroni method was adopted when comparing the results of
short- and long-term follow-ups. All p values were two tailed and a
p < 0.05 was considered signiﬁcant. Statistical analyses were per-
formed using SPSS software (SPSS Inc., Chicago, IL, USA).3. Results
3.1. Effectiveness of STN-DBS (levodopa off/DBS on compared with
preoperative levodopa off) (Table 2, Fig. 1)
3.1.1. UPDRS Part I: mentality
Signiﬁcant improvement was noted within the ﬁrst 2 years after
surgery (p < 0.001). No signiﬁcant improvement was observed in
the 7th year after surgery (Table 2, Fig. 1).
3.1.2. UPDRS Part II: ADL and SEADL
Signiﬁcant improvement on the UPDRS Part II was observed
within 7 years after STN-DBS (p< 0.001 at the 1st year, 2nd year, andFig. 2. Scores on the UPDRS Parts I, II, III, and IV during different follow-up periods with lev
Rating Scale.5th year; p < 0.01 at the 7th year). However, effects of DBS on SEADL
declined after the 5th year (p< 0.05) andwere diminished in the 7th
year postoperatively (statistically nonsigniﬁcant).
3.1.3. UPDRS Part III: motor function
With levodopa off/DBS on, the UPDRS Part III score improved
signiﬁcantly within 7 years of follow-up (p< 0.001). Decrements in
the degree of improvement were observed on Part III axial symp-
toms after the 5th year.
3.1.4. UPDRS Part IV: levodopa treatment complications
Signiﬁcant improvement was noted within 7 years after STN-
DBS surgery.3.2. LEDD reduction
Signiﬁcant reductionwas noted in the LEDD within 7 years after
STN-DBS surgery (p < 0.001 in the ﬁrst 2 years, and p < 0.01 at the
5th year and 7th year; Table 2).odopa off/DBS off. DBS ¼ deep brain stimulation; UPDRS ¼ Uniﬁed Parkinson's Disease
Table 4
Adverse effects after STN-DBS.
Postoperative morbidity (N ¼ 120) N %
Mortality 0 0.0
Adverse effects related to stimulation
Hypophonia 25 20.8
Dyskinesias 23 19.2
Dysarthria 18 15.0
Sialorrhea 17 14.2
Decreased memory 16 13.3
Eyelid apraxia 7 5.8
Increased libido 5 4.2
Dystonia 5 4.2
Paresthesias 4 3.3
General neurological and surgical complications
Weight gain 33 27.5
Perioperative confusion 14 11.7
Mania/hypomania 11 9.2
Depression 7 5.8
Pulmonary edema 3 2.5
Seizures 1 0.8
Deep vein thrombosis 1 0.8
Hemorrhage 4 3.3
Asymptomatic 2 1.7
Symptomatic, total recovery 1 0.8
Symptomatic, partial recovery 1 0.8
Hardware-related complications
Lead problems 5 4.2
Leads that needed to be repositioned (Unilateral) 4 3.3
Leads that needed to be repositioned (Bilateral) 1 0.8
Infections of the hardware 2 1.7
Battery failure 2 1.7
IPG migration 1 0.8
Wire revision 6 5.0
STN-DBS ¼ subthalamic deep brain stimulation, data presented as number
(percentage).
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preoperative levodopa off) (Table 3, Fig. 2)
3.3.1. UPDRS Part I: mentality
Deterioration was noted after the 5th year of STN-DBS, although
it was not statistically signiﬁcant (Table 3, Fig. 2).
3.3.2. UPDRS Part II: ADL and SEADL
Scores on both UPDRS Part II and SEADL deteriorated signiﬁ-
cantly after the 5th year of STN-DBS (p < 0.01 and p < 0.001 at the
5th year and 7th year, respectively).
3.3.3. UPDRS Part III: motor function
Scores for Part III and all subitems deteriorated compared with
the preoperative levodopa off score after the 5th year. Bradykinesia
was signiﬁcantly worse at the 5-year and 7-year follow-ups
(p < 0.05 and p < 0.01, respectively) and the axial component
was signiﬁcantly worse at the 7-year follow-up (p < 0.05).Table 5
Stimulation parameters during different follow-up periods.
1 year 2 years
Ch1 (N ¼ 55) Ch2 (N ¼ 53) Ch1 (N ¼ 48) Ch2 (N ¼ 4
Mean  SD Mean  SD Mean  SD Mean  SD
Voltage 3.2  0.6 3.1  0.7 3.4  0.6 3.4  0.
Pulse width 62.2  7.9 61.1  5.8 62.5  8.4 63.7  9.
Frequency 139.4  16.6 139.0  16.4 147.4  20.1 147.7  20
Data presented as mean  SD, Ch: channel; *p < 0.05, comparison with 1 year.3.3.4. UPDRS Part IV: levodopa treatment complications
Persistent improvement was noted within 7 years of STN-DBS,
although it was not statistically signiﬁcant.
3.4. Adverse effects after STN-DBS (Table 4)
High incidences of stimulation side effects, such as hypophonia
(20.8%), dysarthria (15%), sialorrhea (14.2%), and decreased mem-
ory (13.3%) were observed (Table 4). However, most of these were
transient, and could be improved by changing stimulation param-
eters and medications. The most serious adverse effect was intra-
cranial hemorrhage (N ¼ 4, 3.3%), but only one patient had a
sequela. Patients who experienced postoperative pulmonary
edema (N¼ 3), deep vein thrombosis (N¼ 1), and seizure (N¼ 1) all
recovered well. Postoperative depression (N ¼ 7), mania/hypoma-
nia (N ¼ 11), and perioperative confusion (N ¼ 14) were transient.
Five patients with suboptimally placed electrodes had revisions.
Implants were needed to be removed in one of the two patients
with infection. Two patients with standard stimulation parameters
experienced early termination of the implantable pulse generator
battery. No deaths were reported during this study.
3.5. DBS stimulation parameters during 7 years of follow-up
(Table 5)
Stable voltage and pulsewidthweremaintained through 7 years
of follow-up (Table 5). A signiﬁcation reduction in the stimulation
frequency was noted at the 7th year compared with the 1st year
postoperatively (139.416.6 Hz and 120.6 22.4 Hz, at the 1st year
and 7th year, respectively; p < 0.05).
4. Discussion
STN-DBS had signiﬁcant beneﬁcial effects on all cardinal motor
symptoms of PD as well as on ADL in this 7-year study. However,
the signiﬁcant effects on axial symptoms faded after the 5th year.
This may also have resulted from the high incidence of hypophonia,
dysarthria, and sialorrhea during this study period. These ﬁndings
suggest disease progression, in which axial symptoms are more
complicated and may involve associative circuits [12]. This is
especially true with levodopa off/DBS off, and compared with
preoperative off; all cardinal symptoms of motor components
deteriorated after the 5th year. Furthermore, bradykinesia and axial
symptoms were signiﬁcantly poorer at the 5th year and 7th year
than preoperatively. These ﬁndings also suggest that STN-DBS does
not provide a neuroprotective effect against PD, and the results are
consistent with the natural progression of PD [4]. Zibetti et al [7]
and Merola et al [13] demonstrated a sustained DBS effect on car-
dinal motor symptoms over 9 years; however, this might have been
due to an inadequate period with the battery turned off prior to
assessment. Our protocol deﬁned a DBS off time of 4 hours prior to
UPDRS assessment, and we could not duplicate their results.5 years 7 years
9) Ch1 (N ¼ 29) Ch2 (N ¼ 30) Ch1 (N ¼ 16) Ch2 (N ¼ 16)
Mean  SD Mean  SD Mean  SD Mean  SD
6 3.5  0.4 3.6  0.4 3.7  0.5 3.4  0.6
9 63.1  9.3 64.0  10.4 65.6  12.1 63.8  10.2
.0 130.7  23.1 131.2  22.9 120.6  22.4* 120.6  22.4*
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be superior to globus pallidus internal (GPi) segment stimulation
for most cardinal symptoms of PD [14], GPi-DBS may have a su-
perior effect on axial symptoms, such as speech, posture instability,
and gait [9,11]. In a randomized blinded study, Burchiel et al [15]
and Anderson et al [16] showed that L-dopa axial symptoms were
clinically improved in GPi segment but not STN stimulation in pa-
tients with advanced PD. A large, multicenter cohort study on
advanced PD patients conducted by Rodriguez-Oroz et al [17]
showed that although both STN and pallidal stimulation had
long-term effects on motor symptoms, axial symptoms became
worse in the STN stimulation group. The pedunculopontine nucleus
is believed to be involved in the modulation of locomotor activity
and may be another target for DBS that provides a synergistic effect
on devastating and treatment-resistant posture instability [18e21].
In this study, cognitive function was stable over 7 years and this
somewhat contrasts with previous long-term results [13]. This
might be due to a short disease duration at the time of surgery and
a short follow-up period. A high incidence of transient mania/hy-
pomania and dyskinesia soon after the surgery might be due to the
current diffusion effect within STN and an add-on effect of stimu-
lation with pre-existing dopaminergic therapy [22]. Postoperative
dual management of DBS settings and medications may be crucial
to a satisfactory outcome [23].
During the evolution of PD, axial symptoms remain a critical
problem. Among axial symptoms, verbal ﬂuency may be affected
negatively by STN-DBS. Changes in motor symptoms show a strong
dependency on the frequency of stimulation [24]. De Gaspari et al
[25] and Wojtecki et al [26] showed that, unlike high-frequency
stimulation, low-frequency (10 Hz) stimulation has a positive
modulation effect on verbal ﬂuency. Because of the high incidence
of hypophonia/dysarthria noted in this study, the stimulation fre-
quency in these patients was subsequently reduced during the 7-
year follow-up period. We did observe better speech in these pa-
tients, which echoed Wojtecki’s results. Stefani et al [27] demon-
strated that the success of PPN-DBS in PD gait performance is also
related to low-frequency (25 Hz) stimulation. Although the stim-
ulation targets are different, this may give us a clue to harness
speech disability in addition to parameter adjustment.
Although DBS is efﬁcacious for the management of various
movement disorders, its mechanism of action remains unknown
and is worthy of study [28]. Previous studies suggest that effective
DBS over-rides oscillatory pathological activity and replaces it with
more regularized neuronal ﬁring patterns [29]. The most likely
mechanism of DBS is stimulation-induced modulation of patho-
logical network activity [30]. Several human and animal studies
also support the disease-modifying effects of STN-DBS on
dopaminergic-related symptoms in the early-stage PD [9,13,31].
The progression of nondopaminergic responsive symptoms such as
speech, gait, and mood in the long term suggests that STN-DBS
modiﬁes neuronal circuits and their individual neuronal types to
different degrees.
This is a cross-sectional study with a representative subset of
120 patients with PD who underwent STN-DBS and was followed
up for a speciﬁc period. Although some data were missing in this
retrospective study that may have contributed to bias, we found
consistent results compared with other published studies [23].
Unlike a longitudinal study, this study cannot show the true natural
course of this subset of patients within a 7-year study period. We
also could not ﬁnd a relationship between axial motor symptom
deterioration and the high incidence of hypophonia/dysarthria/
sialorrhea, and deterioration of ADL with time in the present study.
In conclusion, the long-term effects of DBS on motor disability
are promising. DBS showed uneven beneﬁcial effectiveness, and
least improvement in axial symptoms and verbal ﬂuency. Thedisease progressed slowly despite signiﬁcant positive effects of DBS
on the cardinal motor disability symptoms of PD and on QoL. ADL
and QoL improved remarkably after STN-DBS surgery, but these
beneﬁts faded after 5 years. When axial symptoms are the major
presentations, clinicians should bear in mind the shortcomings of
DBS in order to meet patient expectations.
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